DevvStream
Surf Air Mobility

Plug Into More Green Stock News

Tap into the pulse of emerging green sectors every morning. Top daily headlines from clean energy, cleantech, cannabis, and sustainable transport stocks:

Please review our Disclaimer and Privacy Policy before subscribing. One-click unsubscribe at any time.

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company’s management team will attend and participate in presentations at the following upcoming investor events:

  • Wells Fargo 2023 Healthcare Conference in Boston, MA on September 6 at 8:45 a.m. ET;
  • Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on September 12 at 4:15 p.m. ET; and
  • H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on September 13 at 10:00 a.m. ET.

Live webcasts of the presentations will be available under the "Events and Presentations" section of the Investors page on the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics 
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.  

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” company by Fierce Biotech and has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston’s top workplaces. For more information about our people, science and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Investor Contact:Media Contact:
  
Justine KoenigsbergTodd Cooper
Vice President, Investor RelationsSenior Vice President, Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. 
857-285-5300857-285-5300

Plug Into More Green Stock News

Tap into the pulse of emerging green sectors every morning. Top daily headlines from clean energy, cleantech, cannabis, and sustainable transport stocks:

Please review our Disclaimer and Privacy Policy before subscribing. One-click unsubscribe at any time.
Surf Air Mobility

Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...

CLICK TO LEARN MORE
GreenPower Motor

GreenPower Motor designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van, and a cab and chassis...

CLICK TO LEARN MORE

COPYRIGHT ©2022 GREEN STOCK NEWS